Background: Ileocolonic expression of IL13RA2 has been identified as a predictive mar-
| INTRODUCTION
The advent of anti-TNF agents has dramatically improved the treatment of inflammatory bowel disease (IBD) in the past two decades. 1 Despite an overall good response to anti-TNF therapy, up to 30% of patients are primary nonresponders. 2 Why patients fail a particular drug is still poorly understood and, more importantly, accurate and clinically validated biomarkers predicting nonresponse are currently lacking. Using microarray experiments, our group previously identified the expression of IL13RA2 messenger ribonucleic acid (mRNA) in mucosal biopsies of IBD patients as a predictive marker for primary nonresponsiveness to infliximab (IFX) therapy, with a higher baseline expression in future nonresponders. 3, 4 Recent data suggest that IL13RA2 on epithelial cells contributes to IBD by negatively influencing goblet cell recovery, goblet cell function and epithelial restoration after injury. 5 Why IL13RA2, which under physiological conditions is not significantly expressed in normal tissue except in testes, 6, 7 interferes with the effect of anti-TNF therapy in IBD is currently unknown.
The present study aimed to identify if the enhanced IL13RA2 signal is anti-TNF specific and if so, why IL13RA2 expression is a predictive marker of efficacy of anti-TNF therapy. First, we studied the IL13RA2 mRNA signal in a new cohort of adalimumab-treated CD patients, and questioned the specificity of its predictive value through RNA-sequencing of inflamed mucosal biopsies of vedolizumab treated patients. We then applied weighted gene co-expression network analysis (WGCNA)-a data mining method designed to study biological networks based on pairwise correlations between variables-on publicly available colonic microarray data of IFX-treated patients, in order to identify the upstream regulators of anti-TNF nonresponse in CD. Finally, predicted mucosal key drivers were quantified on the protein level in serum, prior to first IFX exposure, compared between healers and nonhealers and correlated with serum IFX induction levels.
| MATERIALS AND METHODS

| Patient selection
This study was conducted at the tertiary IBD referral centre of the University Hospitals Leuven (Leuven, Belgium). Inflamed mucosal biopsies of CD patients initiating therapy with IFX, adalimumab or vedolizumab, were taken prior to the first administration, stored in RNALater buffer (Ambion, Austin, TX, USA) and preserved at −80°C.
Similarly, serum of CD patients with active endoscopic disease was taken prior to the first IFX infusion, centrifuged and stored at −20°C. The primary endpoint, response to therapy, was defined as the complete absence of ulcerations. 8 Baseline characteristics of the different therapy cohorts are summarized in Table 1 .
All patients included in the analysis had given written consent to participate in the Institutional Review Board approved IBD Biobank (B322201213950/S53684), collecting serum, biopsies and clinical characteristics among other items.
| Gene expression studies in mucosal biopsies of CD patients
Gene expression profiles at baseline and 4-6 weeks after IFX initiation were obtained from a previously published cohort by our group (GEO GSE16879) using Affymetrix Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, USA) (Cohort A, 17 colonic and 12 ileal biopsies). 4 In a new cohort of adalimumab and vedolizumab treated patients (Cohort B: 8 colonic, 14 ileal biopsies; Cohort C: 11 colonic, 13 ileal biopsies), RNA was extracted from inflamed biopsies using the AllPrep DNA/RNA Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.
The integrity and quantity of total RNA were assessed with a 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA) and a Nanodrop ELISA kit (HK348, Hycult Biotech, Uden, the Netherlands). IFX serum levels were measured using an ELISA (apDia, Turnhout, Belgium) on an automated ELISA processing system.
| Statistical analysis
All analyses were carried out using R version 3. A P < 0.05 was considered statistically significant.
| RESULTS
| Increased IL13RA2 expression is unique to anti-TNF nonhealers
In cohort A (n = 29, originating from a previously published cohort 4 ), mucosal IL13RA2 mRNA expression prior to the start of IFX therapy was significantly upregulated in future nonhealers (P = 7.7 × 10 to the lack of alternative splicing in humans. 20, 21 Serum CHI3L1 and IL-13 were not significantly different between healers and nonhealers at baseline (P = 0.1, P = 0.3 respectively) ( Figure S2A,B) , whereas a significant difference in sTREM1 could be observed (P = 0.02) as described earlier ( Figure S2C ). 22 
| DISCUSSION
IL13RA2 mRNA in intestinal mucosal tissues has been identified as a predictive biomarker for anti-TNF responsiveness in IBD. 3, 4, 23, 24 In this study, we further elaborated on these previous findings. First, we could show that high IL13RA2 mRNA expression is specific for prediction of resistance to anti-TNF induced mucosal healing, as we did not find similar accuracy in vedolizumab treated subjects. We further studied how expression of this receptor can be related to the effects of TNF neutralization. Instead of purely focusing on top differentially expressed genes, we therefore applied a co-expression network approach on publicly available transcriptomic data of IFXtreated CD patients, providing novel insights in anti-TNF nonresponsiveness. Subtle but biologically relevant differences at the top of a pathophysiological cascade can have important amplified downstream consequences which are not always picked up using differential gene expression analysis, but need more detailed network analysis. In accordance with some recent observations, 22, 25 TREM1 signalling was one of the pivotal pathways upregulated in nonresponders. However, on an upstream level, TNF seemed the most dominant director, influencing several downstream pathways. TNF, the key upstream regulator driving the biological processes associated with anti-TNF nonresponsiveness in this network analysis, has previously been documented to influence IL13RA2 expression.
26,27
The increased mucosal IL13RA2 mRNA expression in anti-TNF nonresponders can therefore be seen at least partly as a downstream effect of the increased mucosal TNF burden. The significant IFX-induced decrease in IL13RA2 expression in healers is another indirect proof suggesting that TNF is largely responsible for IL13RA2 mRNA levels. One could consider these findings on increased TNF burden in future nonresponders as being in conflict to previous findings demonstrating a significant enrichment of mucosal membrane-bound TNF (mTNF)-positive immune cells in future responders. 28 However, due to the design of the current study, we could not discriminate between mTNF and soluble TNF (sTNF) at the mRNA level, and only report the overall TNF burden. An increased mucosal mTNF with decreased sTNF expression in future responders could therefore not be excluded. Furthermore, the increased mucosal TNF mRNA expression in future nonresponders is in line with previous conclusions from the ATLAS-study, which demonstrated that in moderate to severely inflamed tissue, tissue TNF is not sufficiently neutralized by normal doses of anti-TNF agents, and high mucosal levels of TNF serve as a sink for anti-TNF. 29 The lower serum TNF levels in future nonresponders and its significant correlation with CRP do not come as a surprise, as elevated baseline CRP levels are known to be a predictor of anti-TNF responsiveness. [30] [31] [32] [33] Because of the clear correlation between CRP and serum TNF, the inverse correlation observed between serum TNF and IFX serum levels is similar to the inverse correlation between serum levels and CRP documented earlier.
29,34
The higher mucosal TNF burden in future nonhealers is perhaps not sufficient to consider these patients true anti-TNF failures, as tissue anti-TNF concentrations may be insufficient for these patients to neutralize all tissue TNF. Because of the known mismatch between serum and tissue anti-TNF levels, especially in patients with active disease, 29 we hypothesize that targeting a higher serum trough level above the 7.0 μg/mL upper limit of the therapeutic window might better neutralize tissue TNF and hence increase mucosal healing rates, especially in patients with a high mucosal IL13RA2 expression.
Retrospective data already suggested that higher trough levels are safe and result in better endoscopic outcomes. [35] [36] [37] [38] Similarly, recent prospective data from the UK PANTS study also demonstrated the beneficial impact of higher post-induction serum levels on 1-year outcome in anti-TNF-treated patients. 39 Future studies should therefore randomize patients with high mucosal expression of IL13RA2 or high mucosal TNF burden between normal or increased doses of IFX, and evaluate if response rates can be improved by increased exposure, especially in those patients with a high baseline IL13RA2
expression.
In conclusion, we confirmed the potential use of mucosal IL13RA2 expression as an anti-TNF specific predictive marker for mucosal healing. Based on our network approach of transcriptomic data and the current literature, we propose that a high expression of IL13RA2 mRNA to a large extent (if not exclusively) reflects higher TNF production in the tissue. It remains to be explored if higher anti-TNF exposure in patients with increased baseline IL13RA2 expression can neutralize this increased TNF burden and hence then results in successful healing. For regulatory purposes, clinical trials investigate only a limit number of different dosages of a particular drug, in order to achieve the best outcome for the majority of patients. However, this "one-size fits all" principle does not take into consideration pharmacokinetic variability, which has already been proven to be of high importance in anti-TNF therapy. 40 Future research, studying higher IFX exposure based on personalised pharmacokinetic models, including biomarkers as for instance mucosal IL13RA2 and whole blood TREM1 expression, are therefore eagerly awaited.
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